Factors That Prevent Progression to Transcatheter Aortic Valve Implantation (TAVI).


Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 28 03 2018
revised: 14 05 2018
accepted: 13 07 2018
pubmed: 11 9 2018
medline: 18 12 2019
entrez: 11 9 2018
Statut: ppublish

Résumé

Transcatheter aortic valve implantation (TAVI) is increasingly used for intermediate- and high-risk patients with severe symptomatic aortic stenosis (AS). However, safe undertaking of the procedure may be precluded by various anatomic factors. This study sought to identify prevalence of factors that prevent progression to TAVI. TAVI candidates with severe AS undergoing workup coronary angiography and iliac vessel angiography (±cardiac-gated CT) were identified and factors precluding TAVI were reviewed retrospectively from a single-centre cardiac database over a 10-year period. 197 patients were included; mean age was 81.5±6.5years (±SD); 46.2% were male. 26.9% of TAVI candidates could not proceed to femoral access TAVI due to various factors including unsuitable peripheral vasculature (13.2%), untreated coronary artery disease (CAD) deemed high risk for TAVI (8.1%), unfavourable aortic characteristics (4.1%), and low-lying coronary ostia (1.5%). Factors associated with unsuitable femoral vasculature included female gender (p<0.01) and any CAD (p=0.03). Factors associated with the presence of unrevascularised CAD included male gender (p<0.01), estimated glomerular filtration rate (eGFR)<30mL/min/1.73m Non-progression to TAVI among higher risk patients with severe AS has become less common over the last 10 years with improvements in operator experience, lower profile devices, and wider ranges of valve sizes.

Sections du résumé

BACKGROUND BACKGROUND
Transcatheter aortic valve implantation (TAVI) is increasingly used for intermediate- and high-risk patients with severe symptomatic aortic stenosis (AS). However, safe undertaking of the procedure may be precluded by various anatomic factors. This study sought to identify prevalence of factors that prevent progression to TAVI.
METHODS METHODS
TAVI candidates with severe AS undergoing workup coronary angiography and iliac vessel angiography (±cardiac-gated CT) were identified and factors precluding TAVI were reviewed retrospectively from a single-centre cardiac database over a 10-year period.
RESULTS RESULTS
197 patients were included; mean age was 81.5±6.5years (±SD); 46.2% were male. 26.9% of TAVI candidates could not proceed to femoral access TAVI due to various factors including unsuitable peripheral vasculature (13.2%), untreated coronary artery disease (CAD) deemed high risk for TAVI (8.1%), unfavourable aortic characteristics (4.1%), and low-lying coronary ostia (1.5%). Factors associated with unsuitable femoral vasculature included female gender (p<0.01) and any CAD (p=0.03). Factors associated with the presence of unrevascularised CAD included male gender (p<0.01), estimated glomerular filtration rate (eGFR)<30mL/min/1.73m
CONCLUSIONS CONCLUSIONS
Non-progression to TAVI among higher risk patients with severe AS has become less common over the last 10 years with improvements in operator experience, lower profile devices, and wider ranges of valve sizes.

Identifiants

pubmed: 30197258
pii: S1443-9506(18)31830-4
doi: 10.1016/j.hlc.2018.07.004
pii:
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1225-1234

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Luke P Dawson (LP)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia.

Misha Dagan (M)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia.

Youlin Koh (Y)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia.

Stephen J Duffy (SJ)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia; Department of Epidemiology, Monash University, Melbourne, Vic, Australia.

Dion Stub (D)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Vic, Australia; Department of Epidemiology, Monash University, Melbourne, Vic, Australia.

Philip Lew (P)

Department of Radiology, Alfred Hospital, Melbourne, Vic, Australia.

James A Shaw (JA)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Vic, Australia.

Antony Walton (A)

Department of Cardiology, Alfred Hospital, Melbourne, Vic, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Vic, Australia; Department of Epidemiology, Monash University, Melbourne, Vic, Australia. Electronic address: a.walton@alfred.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH